BioSpace News Archive

FDA

Going it Alone, FDA Authorizes Second Booster for Adults 50 Plus

Without holding a meeting of its vaccines advisory committee, the U.S. Food and Drug Administration (FDA) authorized a fourth booster shot for everyone 50 years of age and older.

March 29, 2022
·
3 min read
·
Mark Terry
Business

Sanofi Commits Potential $6B to IGM (Antibodies) in New Collab

Sanofi and IGM Biosciences inked a collaboration deal for oncology, immunology and inflammation that could surpass $6 billion.

March 29, 2022
·
3 min read
·
Mark Terry
Pharm Country

Lannett Initiates Pivotal Clinical Trial For Biosimilar Insulin Glargine

Lannett Company, Inc. announced that it has initiated the pivotal clinical trial of biosimilar insulin glargine, a product the company is co-developing with its strategic alliance partners within the HEC Group of companies.

March 29, 2022
·
3 min read
Business

TYME Technologies, Inc. Announces Exploration of Strategic Options

TYME Technologies, Inc., an emerging biotechnology company developing cancer metabolism-based therapies, announced that its Board of Directors has decided to explore potential strategic options to enhance stockholder value.

March 29, 2022
·
6 min read
Microbix Invests to Further Scale Its Business

Microbix Biosystems Inc., a life sciences innovator and exporter, announces investment in programs to upgrade, digitize and fully-integrate its Quality Management System and its Enterprise Resource Planning platforms — to better enable its business growth trajectory.

March 29, 2022
·
5 min read
Business

Rezolute Joins the Rare Disease Company Coalition

Rezolute, Inc., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, announced that it has joined the Rare Disease Company Coalition.

March 29, 2022
·
2 min read
Business

SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the fourth quarter and full year ended on December 31, 2021.

March 29, 2022
·
17 min read
Business

Kala Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Kala Pharmaceuticals, Inc. today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

March 29, 2022
·
27 min read
Drug Development

Ocuphire Announces Positive Topline Results from MIRA-3 Phase 3 FDA Registration Trial for Nyxol® in the Reversal of Mydriasis

Ocuphire Pharma, Inc. today announced positive topline results in the MIRA-3 trial, the company’s second Phase 3 registration trial investigating its product candidate Nyxol® for the reversal of pharmacologically-induced mydriasis (dilation of pupil).

March 29, 2022
·
12 min read
BioMidwest

New Video Series “PSMA PET/CT TODAY” Discusses the Future of Prostate Cancer Care with Leading Experts

Hosted by Dr. Neal Shore, Chief Medical Officer of Surgical Oncology and Urology with GenesisCare and director at Carolina Urologic Research Center, the interview series explores the new field of PSMA PET/CT imaging and its potential impact on the future of prostate cancer care.

March 29, 2022
·
5 min read